- AstraZeneca and Daiichi Sankyo secure EU approval for Enhertu, expanding treatment options for breast cancer patients.
- Analysts forecast significant upside potential for AstraZeneca's stock, with an average target price of $87.28.
- GuruFocus' GF Value estimate suggests a promising 33.79% upside for AstraZeneca.
AstraZeneca (AZN, Financial) in collaboration with Daiichi Sankyo has achieved a notable milestone by obtaining EU approval for Enhertu. This approval permits its use as a monotherapy in treating certain metastatic breast cancer types. Specifically designed to target HER2-low and HER2-ultralow expressions, Enhertu has shown to enhance progression-free survival rates in clinical trials. This regulatory endorsement allows more extensive application across diverse patient groups throughout the European Union.
Wall Street Analysts Forecast
According to projections provided by 10 analysts, AstraZeneca PLC (AZN, Financial) is set for a promising trajectory with an average price target of $87.28. Forecasts show the potential for the stock to reach as high as $97.00 or dip to $67.00. This average target signifies a notable upside of 34.49% from its current trading price of $64.90. Investors seeking further details can visit the AstraZeneca PLC (AZN) Forecast page.
The consensus recommendation across 12 brokerage firms positions AstraZeneca PLC (AZN, Financial) with an average rating of 1.8, indicating an "Outperform" status. This rating is based on a scale from 1 to 5, where 1 represents a Strong Buy and 5 signals a Sell.
Further bolstering this outlook, GuruFocus provides an estimated GF Value for AstraZeneca PLC (AZN, Financial) at $86.83 in the coming year. This estimate predicts a potential upside of 33.79% from its current price of $64.90. The GF Value is derived from historical trading multiples and considers past business growth alongside future performance estimates. More in-depth data is accessible on the AstraZeneca PLC (AZN) Summary page.
